News
MNK
--
0.00%
--
American Well, MediciNova among major healthcare gainers, AC Immune, Wave Life Sciences leads losers' pack
Gainers: American Well (AMWL) +17%, MediciNova (MNOV) +13%, Mallinckrodt (MNK) +7%, Capricor Therapeutics (CAPR) +8%, Adamas Pharmaceuticals (ADMS) +6%.Losers: AC Immune (ACIU) -42%, Wave Life Sciences (WVE) -34%, Rockwell Medical (RMTI) -28%, Aurora Cannabis (ACB) -23%, NanoVibronix NAOV -15%.
Seekingalpha · 1d ago
Mallinckrodt: A Series Of Unfortunate Events
Terlipressin's rejection is a huge blow to the diversification effort, but likely a delay rather than a scrapping of the entire program.CMS lawsuit remains the biggest overhang, but also an opportunity if it goes in the company's favour.MNK remains grossly undervalued with a conservative target of $8, representing >900% upside.With a strong legal case and the interests of all parties to keep the company solvent, I remain bullish on the prospect of a turnaround.
Seekingalpha · 2d ago
Nestle Acquiring Aimmune, And Other News: The Good, Bad And Ugly Of Biopharma
Aimmune to be acquired by Nestle for $2.6 billion.Mallinckrodt receives a CRL for Terlipressin.Cassava reports positive final data for Alzheimer’s treatment.
Seekingalpha · 4d ago
Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall
Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.
Zacks · 09/15 14:59
Mid-Afternoon Market Update: Dow Rises 350 Points; Cassava Sciences Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 1.27% to 28,016 while the NASDAQ rose 1.74% to 11042.51. The S&P also rose, gaining 1.41% to 3,387.94.
Benzinga · 09/14 18:32
Mid-Day Market Update: Immunomedics Jumps Following Acquisition News; Mallinckrodt Shares Slide
Midway through trading Monday, the Dow traded up 1.38% to 28046.83 while the NASDAQ rose 2.41% to 11,114.71. The S&P also rose, gaining 1.73% to 3,398.74.
Benzinga · 09/14 16:07
Immunomedics, Cassava Sciences leads gainers pack, Nano-X Imaging, Teligent among major losers
Gainers: Immunomedics (IMMU) +101%, Cassava Sciences, (SAVA) +78%, Vaxart (VXRT) +28%, Mersana Therapeutics (MRSN) +17%, Venus Concept (VERO) +15%.Losers: Nano-X Imaging (NNOX) -14%, Teligent (TLGT) -12%, Mallinckrodt (MNK) -12%, Kala Pharmaceuticals (KALA) -12%, Co-Diagnostics (CODX) -11%.
Seekingalpha · 09/14 15:06
A Look Into Mallinckrodt's Debt
Over the past three months, shares of Mallinckrodt (NYSE: MNK) decreased by 54.00%. Before having a look at the importance of debt, let us look at how much debt Mallinckrodt has.Mallinckrodt's Debt Based on Mallinckrodt's balance sheet as of August 4, 2020, long-term debt is at $5.22 billion
Benzinga · 09/14 14:45
Mallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the company's New Drug Application (NDA) seeking approval for the investigational agent terlipressin to treat adults
PR Newswire · 09/14 11:45
The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations
After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off.
Benzinga · 09/06 17:25
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Podcasts, Stitcher and Spotify (click the highlighted links). The tech sector will be in focus again in the week ahead as investors gauge if short-term pandemic plays like Zscaler (ZS) Palo Alto Networks (PANW), Fortinet (FTNT), Zoom Video (ZM) and DocuSign (DOCU) are good for the longer haul
Seekingalpha · 09/05 12:21
Why Is Mallinckrodt (MNK) Down 3.9% Since Last Earnings Report?
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/03 16:31
Implied Volatility Surging for Mallinckrodt (MNK) Stock Options
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
Zacks · 09/03 13:05
Mallinckrodt Is Just Too Complex For My Liking
Mallinckrodt has two upcoming approvals, a $126mn market cap, $818mn in cash, and a whopping $5.24bn in debt.The trial data supporting the Terlipressin approval is complex, and the advisory committee was split 7-8 on the decision.However, the financials are just too complex for me to bother with MNK at this time.
Seekingalpha · 09/03 13:03
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August was a disappointing month as far as regulatory decisions are concerned. The FDA turned down several applications, citing different reasons.
Benzinga · 09/01 22:05
California Assembly Passes Generic-Drug Cost-Reduction Bill
MotleyFool.com · 09/01 18:37
AbbVie under pressure on House Committee subpoena in price-fixing probe
AbbVie (ABBV -2.6%) is under modest pressure on below-average volume in apparent reaction to reports that it has received a subpoena from the U.S. House Ov
Seeking Alpha - Article · 09/01 14:25
Coalition to Bill Barr: Imprison pharma executives for their roles in opioid crisis
A letter addressed to Attorney General Bill Barr and the U.S. Department of Justice is calling out major pharmaceutical companies for their role in the U.S. opioid crisis. 
Yahoo Finance · 08/31 20:52
Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma
Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation.Calliditas Therapeutics inks deal for Genkyotex Acquisition.Cortexyme announces advancement of Alzheimer’s trial.
Seekingalpha · 08/16 08:10
Mallinckrodt up 11% on merger rumors
Mallinckrodt ([[MNK]] +11.1%) perks up on modestly higher volume in apparent response to social media chatter that it is in merger talks with an unnamed company.The company has been under
Seekingalpha · 08/13 16:08
Webull provides a variety of real-time MNK stock news. You can receive the latest news about Mallinckrodt Plc through multiple platforms. This information may help you make smarter investment decisions.
About MNK
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
More